An important role of cutaneous lymphatic vessels in coordinating and promoting anagen hair follicle growth.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 08 04 2019
accepted: 12 07 2019
entrez: 26 7 2019
pubmed: 26 7 2019
medline: 1 4 2020
Statut: epublish

Résumé

The lymphatic vascular system plays important roles in the control of tissue fluid homeostasis and immune responses. While VEGF-A-induced angiogenesis promotes hair follicle (HF) growth, the potential role of lymphatic vessels (LVs) in HF cycling has remained unknown. In this study, we found that LVs are localized in close proximity to the HF bulge area throughout the postnatal and depilation-induced hair cycle in mice and that a network of LVs directly connects the individual HFs. Increased LV density in the skin of K14-VEGF-C transgenic mice was associated with prolongation of anagen HF growth. Conversely, HF entry into the catagen phase was accelerated in K14-sVEGFR3 transgenic mice that lack cutaneous LVs. Importantly, repeated intradermal injections of VEGF-C promoted hair growth in mice. Conditioned media from lymphatic endothelial cells promoted human dermal papilla cell (DPC) growth and expression of IGF-1 and alkaline phosphatase, both activators of DPCs. Our results reveal an unexpected role of LVs in coordinating and promoting HF growth and identify potential new therapeutic strategies for hair loss-associated conditions.

Identifiants

pubmed: 31344105
doi: 10.1371/journal.pone.0220341
pii: PONE-D-19-09938
pmc: PMC6657912
doi:

Substances chimiques

Vascular Endothelial Growth Factor C 0
vascular endothelial growth factor C, mouse 0
Vascular Endothelial Growth Factor Receptor-3 EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0220341

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Am J Pathol. 2003 Feb;162(2):575-86
pubmed: 12547715
Gastroenterology. 2015 Jun;148(7):1438-51.e8
pubmed: 25754161
Nat Med. 2014 Aug;20(8):847-56
pubmed: 25100530
J Investig Dermatol Symp Proc. 2011 Dec;15(1):24-32
pubmed: 22076324
Adv Drug Deliv Rev. 2014 Jul;74:12-8
pubmed: 24524932
Keio J Med. 2012;61(2):47-56
pubmed: 22760023
Exp Dermatol. 2015 May;24(5):388-90
pubmed: 25690790
Am J Pathol. 2007 Apr;170(4):1178-91
pubmed: 17392158
J Control Release. 2013 Dec 10;172(2):550-7
pubmed: 23665257
J Dermatol Sci. 2014 May;74(2):125-34
pubmed: 24582062
Exp Mol Pathol. 2016 Apr;100(2):332-6
pubmed: 26960166
PLoS Biol. 2014 Dec 23;12(12):e1002002
pubmed: 25536657
J Dermatol Sci. 2006 Jan;41(1):11-9
pubmed: 16216466
J Investig Dermatol Symp Proc. 1999 Dec;4(3):207-10
pubmed: 10674367
Am J Pathol. 2003 Jun;162(6):1951-60
pubmed: 12759251
J Clin Invest. 2005 Feb;115(2):247-57
pubmed: 15668734
Nat Med. 2014 Sep;20(9):1043-9
pubmed: 25129481
Exp Cell Res. 2012 Aug 15;318(14):1633-40
pubmed: 22659165
J Invest Dermatol. 2001 Jul;117(1):3-15
pubmed: 11442744
Carcinogenesis. 2006 Sep;27(9):1729-38
pubmed: 16597644
J Natl Cancer Inst. 2002 Jun 5;94(11):819-25
pubmed: 12048269
Lab Invest. 1989 Mar;60(3):365-9
pubmed: 2927078
Cell Stem Cell. 2009 Feb 6;4(2):155-69
pubmed: 19200804
Exp Dermatol. 2013 Jul;22(7):496-9
pubmed: 23800066
J Immunol. 2012 Sep 1;189(5):2181-90
pubmed: 22844119
Nat Rev Mol Cell Biol. 2012 Jan 23;13(2):103-14
pubmed: 22266760
J Exp Med. 2010 Sep 27;207(10):2255-69
pubmed: 20837699
J Clin Invest. 2001 Feb;107(4):409-17
pubmed: 11181640
Trends Mol Med. 2001 Jul;7(7):293-301
pubmed: 11425637
Nat Med. 2001 Feb;7(2):199-205
pubmed: 11175851
Oncotarget. 2016 Jun 28;7(26):39421-39435
pubmed: 27270646
Angiogenesis. 2014 Apr;17(2):359-71
pubmed: 24212981
Eur J Clin Invest. 2011 May;41(5):487-97
pubmed: 21128936
J Dermatol Sci. 2010 Jan;57(1):2-11
pubmed: 20022473
J Invest Dermatol. 2003 Jan;120(1):14-9
pubmed: 12535193
Science. 1997 May 30;276(5317):1423-5
pubmed: 9162011
Br J Dermatol. 2004 Feb;150(2):186-94
pubmed: 14996087
J Immunol. 2010 Jan 15;184(2):535-9
pubmed: 20018627
J Investig Dermatol Symp Proc. 2000 Dec;5(1):14-9
pubmed: 11147669
J Dermatol Sci. 1994 Jul;7 Suppl:S55-72
pubmed: 7999676
J Clin Invest. 2014 Sep;124(9):3863-78
pubmed: 25105363
Blood. 2011 Apr 28;117(17):4667-78
pubmed: 21364190
J Invest Dermatol. 2000 May;114(5):909-16
pubmed: 10771470
J Korean Med Sci. 2007 Apr;22(2):283-9
pubmed: 17449938
Oncogene. 2012 Oct 18;31(42):4499-508
pubmed: 22179834
J Clin Invest. 2014 Mar;124(3):943-52
pubmed: 24590280
Arch Dermatol Res. 2009 Jun;301(5):357-65
pubmed: 19238412
Nat Rev Mol Cell Biol. 2007 Jun;8(6):464-78
pubmed: 17522591
Cell. 1997 Feb 21;88(4):435-7
pubmed: 9038334
J Am Acad Dermatol. 2005 Jan;52(1):152-6
pubmed: 15627100
Blood. 2007 Feb 1;109(3):1010-7
pubmed: 17032920
Growth Horm IGF Res. 2014 Apr-Jun;24(2-3):89-94
pubmed: 24797500

Auteurs

Sun-Young Yoon (SY)

Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Zurich, Switzerland.
School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.

Lothar C Dieterich (LC)

Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Zurich, Switzerland.

Sinem Karaman (S)

Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Zurich, Switzerland.

Steven T Proulx (ST)

Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Zurich, Switzerland.

Samia B Bachmann (SB)

Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Zurich, Switzerland.

Carol Sciaroni (C)

Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Zurich, Switzerland.

Michael Detmar (M)

Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH